Improving outcomes for people with skin tumours including melanoma

Process
• Audit of adherence to protocols in the management of these
patients.
• Evidence of agreement between various MDTs regarding
protocols in relationship to the various skin cancers; this may
include skin cancer MDTs, soft tissue sarcoma MDTs, head and
neck MDTs and haematology MDTs.
Improving Outcomes for
People with Skin Tumours
including Melanoma
Management of special
groups
• Evidence that patients have been given written information
describing the procedures they undergo, and that this
information covers the resultant risks as well as anticipated
benefits.
• Surveys of patients’ and carers’ views on their information and
support needs, as well as their experience of services.
Outcome
• Proportion of patients recruited to clinical trials.
• Quality of care and outcomes for all patients with skin cancer.
E. Resource implications
6
Generic recommendations for patients with
uncommon risk factors or rare cancers
These recommendations will have an impact on MDTs and staffing
levels, included in the additional staff required as a result of the
guidance, as detailed in the chapter on ‘Organisation of skin cancer
services’.
The improved coordination of care and treatment of these patients
may lead to cost savings that it is not possible to calculate.
Genetic predisposition
This recommendation concerns rare conditions including familial MM,
Gorlin’s syndrome and xeroderma pigmentosum (XP). In some
networks there may be capacity within existing genetics services. This
will require further investigation by local commissioners.
Guidance on cancer services: skin tumours including melanoma
125